Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate

Human Pathology

Volumn 33, Issue 3, 2002, Pages 299-306

  Royuela, Mar ^a   Arenas, Maria Isabel ^a   Bethencourt, Fermin R ^a   Fraile, Benito ^a   Paniagua, Ricardo ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

ERK; JNK; MAPKs; P38; Prostate

Indexed keywords

GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

EID: 0036235788     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.32227     Document Type: Article

References (34)

1. Regulation of transcription by MAP kinase cascades
2. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast
3. Mitogen-activated protein kinase cascades and regulation of gene expression
4. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis
5. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and in inversely related to apoptosis
6. Mitogen-activated protein kinases and apoptosis in PIN
7. Activation of mitogen-activated protein kinase associated with prostate cancer progression
8. Activation of extracellular signal-regulated kinase in human prostate cancer
9. The search for physiological substrates of MAP and SAP kinases in mammalian cells
10. 2-terminal kinases
11. Role of the ATFa/JNK2 complex in Jun activation
12. WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression
13. An essential role for Rho, Rac and Cdc42 GTPases in cell cycle progression through GI
14. The stress-activated protein kinase pathway
15. MEKK1/JNK signaling stabilizes and activates p53
16. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation
17. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblats and phosphorylation in vitro by MAP kinase affects DNA binding activity
18. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma
19. Application of the mononuclear antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma
20. Epidermal growth factor and prostatic carcinoma: An immunohistochemical study
21. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma
22. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia
23. Expression of transforming growth factor α and the epidermal growth factor receptor in human prostate tissues
24. Transforming growth factor β1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia and prostatic carcinoma
25. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: Immunohistochemical comparative analysis
26. Expression of bcl-2, bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation
27. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia
28. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
29. Cytokine levels in seminal plasma
30. Immunoexpression of tumor necrosis factor-α, and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplastic and carcinomatous human prostates
31. The p53 tumor suppressor gene
32. p42-MAP kinase is activated in EGF-stimulated interphase but not in metaphase-arrested HeLa cells
33. A novel human STE-20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway
34. Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I